Molecular Partners (NASDAQ:MOLN – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.01, Zacks reports.
Molecular Partners Stock Performance
Shares of MOLN opened at $4.61 on Friday. Molecular Partners has a 52-week low of $3.53 and a 52-week high of $5.36. The business’s fifty day moving average is $4.06 and its 200-day moving average is $4.23. The firm has a market cap of $186.17 million, a price-to-earnings ratio of -2.70 and a beta of 1.08.
Analyst Upgrades and Downgrades
A number of research analysts recently commented on MOLN shares. Weiss Ratings restated a “sell (d-)” rating on shares of Molecular Partners in a research report on Wednesday, July 8th. HC Wainwright reiterated a “buy” rating on shares of Molecular Partners in a research note on Monday, July 6th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $8.38.
Institutional Trading of Molecular Partners
A hedge fund recently bought a new stake in Molecular Partners stock. SmartHarvest Portfolios LLC bought a new position in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 12,311 shares of the company’s stock, valued at approximately $54,000. Institutional investors own 26.55% of the company’s stock.
About Molecular Partners
Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.
The company’s development pipeline spans infectious diseases, ophthalmology and oncology.
Read More
- Five stocks we like better than Molecular Partners
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
